Tandem Diabetes Care, Inc. (TNDM)
NASDAQ: TNDM · Real-Time Price · USD
17.15
+0.80 (4.89%)
At close: Oct 22, 2026, 4:00 PM EDT
17.09
-0.06 (-0.35%)
Pre-market: Oct 23, 2026, 4:54 AM EDT
Tandem Diabetes Care Revenue
Tandem Diabetes Care had revenue of $254.56M in the quarter ending June 30, 2026, with 5.77% growth. This brings the company's total for the last twelve months to $1.04B, up 3.96% year-over-year. In the year 2025, Tandem Diabetes Care had annual revenue of $1.01B with 7.93% growth. That makes Tandem Diabetes Care the 7,429th largest company in the world by revenue and 1,767th in the United States.
Revenue (ttm)
$1.04B
Revenue Growth
+3.96%
P/S Ratio
1.15
Revenue / Employee
$416,567
Employees
2,500
Market Cap
1.19B
Revenue by Geography
- United States 706.94M 69.7%
- International 307.80M 30.3%
Fiscal year ended Dec 31, 2025 See the full Tandem Diabetes Care breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.01B | 74.53M | 7.93% |
| Dec 31, 2024 | 940.20M | 192.49M | 25.74% |
| Dec 31, 2023 | 747.72M | -53.50M | -6.68% |
| Dec 31, 2022 | 801.22M | 98.42M | 14.00% |
| Dec 31, 2021 | 702.80M | 203.97M | 40.89% |
| Dec 31, 2020 | 498.83M | 136.53M | 37.68% |
| Dec 31, 2019 | 362.31M | 178.44M | 97.05% |
| Dec 31, 2018 | 183.87M | 76.27M | 70.88% |
| Dec 31, 2017 | 107.60M | 23.35M | 27.72% |
| Dec 31, 2016 | 84.25M | 11.40M | 15.65% |
| Dec 31, 2015 | 72.85M | 23.13M | 46.51% |
| Dec 31, 2014 | 49.72M | 20.72M | 71.41% |
| Dec 31, 2013 | 29.01M | 26.53M | 1,072.00% |
| Dec 31, 2012 | 2.48M | - | - |
| Dec 31, 2011 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| QuidelOrtho | 2.67B |
| Enovis | 2.30B |
| CONMED | 1.37B |
| Lumexa Imaging Holdings | 1.04B |
| Bioventus | 581.85M |
| Artivion | 471.47M |
| PROCEPT BioRobotics | 337.34M |
| SI-BONE | 213.60M |
TNDM News
- 9 days ago - Tandem Diabetes price target lowered to $18 from $20 at Mizuho - TheFly
- 16 days ago - Tandem Diabetes initiated with an Equal Weight at Barclays - TheFly
- 21 days ago - Tandem Diabetes Care to Announce Third Quarter 2026 Financial Results on November 5, 2026 - Business Wire
- 23 days ago - Citi cuts Tandem target, opens ‘upside 90-day catalyst watch’ - TheFly
- 25 days ago - Tandem Diabetes says Tandem Mobi now available in 12 international markets - TheFly
- 25 days ago - Tandem Mobi Automated Insulin Delivery System Now Available in Twelve International Markets - Business Wire
- 2 months ago - Tandem Diabetes initiated with an Outperform at William Blair - TheFly
- 2 months ago - Tandem Diabetes price target raised to $24 from $21 at Citi - TheFly